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number D13664) maps to chromosome 13q13.3 
and encodes a secreted 90-kDa protein with an 
amino-terminal cysteine-rich EMI domain (that 
binds type I collagen, fibronectin, and Notch1), 
a tandem repeat of 4 fas1 domains (that bind te-
nascin C and bone morphogenetic protein 1), and 
a carboxyl-terminal domain giving rise to multi-
ple alternative splice variants.7 Together this sug-
gests an extracellular function in cell adhesion 
and migration, for example, as ligands for αVβ3 
and αVβ5 integrins, binding to the extracellular 
matrix (ECM) proteins and cell surfaces and en-
abling attachment and movement. 
The periostin literature suggests a common pat-
tern of function based on its localization during 
tissue development and oncology, response to in-
jury, epithelial-mesenchymal transition, ECM re-
structuring and remodeling. Normal lung devel-
opment involves coordinated periostin expres-
sion,8 and experimental models using periostin 
gene-deleted mice show that periostin is required 
for normal wound repair9 and contributes to the 
pathogenic remodeling in a variety of chronic 
diseases including broncho-pulmonary dyspla-
sia, bleomycin-induced fibrosis, atherosclerosis, 
inflammatory bowel disease, and asthma.10 The 
serum periostin concentration as a systemic bio-
marker of local remodeling is increased in idio-
pathic pulmonary fibrosis7 and predicts disease 
progression.11 Similarly, in severe uncontrolled 
asthma, the serum periostin concentration is 
higher in patients with persistent airflow limita-
tion and has an inverse correlation with postbron-
chodilator forced expiratory volume in 1 second to 
forced vital capacity ratio despite treatment with 
high-dose inhaled corticosteroids,2 and could be 
a diagnostic tool for targeted therapy against the 
remodeling component of refractory Th2/eosin-
ophilic asthma inflammation.4
Periostin gene expression and protein synthesis 
is dynamic and rapidly turned over. It is induced 
by IL-4, IL-13, tumor growth factor (TGF)-β1,12 
TGF-β3, and by the hypoxia-responsive growth 
The recognition of different asthma pheno-
types has helped identify distinct mechanisms of 
pathogenesis and thereby direct a personalized 
approach to therapy.1 Detailed laboratory inves-
tigation of these mechanisms has in turn iden-
tified distinct inflammatory pathways, or endo-
types, which together with phenotype will high-
light further molecular targets for therapy and im-
prove patient stratification. Central to this process 
is biomarker discovery. Periostin is a recognized 
biomarker in asthma,3 and is useful for identifi-
cation of patients with increased clinical bene-
fit from treatment with anti-interleukin (IL)-13 
and anti-immunoglobulin-E (IgE) therapy,3 and 
may be prognostic for increased risk of asthma 
exacerbations and progressive lung function de-
cline.4 It is also a nascent biomarker in chronic 
obstructive pulmonary disease (COPD).5 There is 
a need for further studies in asthma phenotypes 
and COPD, and in this issue of Polish Archives of 
Internal Medicine (Pol Arch Med Wewn), Katarzy-
na Górska et al6 have extended the evaluation of 
periostin to include steroid-naive, mild-to-mod-
erate asthma as well as COPD. In a prospective 
study, they demonstrated that bronchial periostin 
deposition could be identified by immunohisto-
chemistry in healthy biopsy tissue, that this was 
progressively greater in COPD and asthma pa-
tients, and that the amount of bronchial expres-
sion correlated with the periostin concentration 
in exhaled breath condensate (EBC). Although 
patient numbers were small, the study was com-
prehensive and also included periostin concen-
trations quantified in serum and in airway fluids 
derived from sputum and lung lavage, although 
these latter measurements seemed to be of lim-
ited clinical value.
Periostin is a vitamin K-dependent, γ-carbo-
xylated protein and a member of the CCN family 
of matricellular proteins. It was first cloned from 
a mouse calvarial cell line, hence its original des-
ignation as osteoblast-specific factor 2. The hu-
man periostin gene (POSTN; GenBank accession 
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develops, and finally providing the framework for 
aberrant remodeling and chronicity. These func-
tions might not be easily demonstrated in cross-
sectional studies in patients or in a gene-delet-
ed mouse model, and might explain conflicting 
findings. It is possible that these different func-
tions are associated with different periostin splice 
variant isoforms. POSTN can undergo alterna-
tive splicing in its C-terminal region, generating 
isoforms that mediate extended β-zipper bind-
ing interactions with other proteins during re-
modeling.7,16 The function of these unique vari-
ants has only begun to be examined and isoform-
specific expression has been found in a variety of 
cell and tissue types, such as in psoriatic arthritis 
where periostin isoforms are putative biomark-
ers. Also in idiopathic pulmonary fibrosis (IPF), 
there is increased gene-level expression differen-
tial splicing of periostin that has been associat-
ed with clinical progression.7 A more comprehen-
sive understanding of periostin variant function 
in asthma and COPD will undoubtedly yield new 
insight into their pathological processes and re-
veal potential therapeutic strategies.
One practical point with the study of perios-
tin is that different isoforms may be produced 
by cells in different tissues and that some anti-
periostin antibodies may not necessarily detect 
all the isoforms. These reasons may help explain 
the lack of correlation between periostin con-
centrations found in the different airway sam-
ples in the study of Górska et al.6 There is clear-
ly more work to be done to develop isoform-spe-
cific assays, for example, by using liquid chroma-
tography–tandem mass spectrometry, which has 
shown 3 phosphorylation modification sites of 
periostin that might further contribute to sub-
tle functional differences.17 Furthermore, perios-
tin is a γ-carboxylated protein and this has pro-
found effects on protein structure and function, 
which is still to be explored in periostin. Perios-
tin measurement for evaluating airway disease is 
more conveniently done using serum3 rather than 
using sputum or bronchoalveolar lavage. For ex-
ample, periostin is a disulphide-linked protein 
and its immunoreactive detection may6 or may 
not2 be compromised by the use of the reducing 
agent 0.1% dithiothreitol (DTT) to liquefy spu-
tum plugs. This effect may be mitigated by using 
a lower DTT concentration or by using less tox-
ic dithioerythritol. The measurement of serum 
periostin levels in asthma may be compromised 
by additional periostin synthesis contributed by 
comorbidities, such as atopic dermatitis. There-
fore, the observation of Górska et al6 that peri-
ostin can be quantified in EBC and that its con-
centration correlated with airway expression lev-
els suggests that this may become the preferred 
noninvasive technique.
What are the therapeutic options for target-
ing periostin? The in vitro decellularized aber-
rant ECM derived from cultured lung fibroblasts 
from IPF patients, compared with that from non-
fibrotic lung tissue, had a greater impact on gene 
factors angiotensin 11 and fibroblast growth fac-
tor 1. In the lungs, periostin expression colocal-
izes with α-smooth muscle actin suggesting syn-
thesis by myofibroblasts8 and periostin expres-
sion in airway epithelial cells in asthmatic sub-
jects correlated with the extent of subepithelial 
fibrosis.13 Periostin can in turn modulate TGF-β 
function by enhancing airway fibroblast type-1 
collagen production and cross-linking and stiff-
ening of the ECM.13 In addition to this matricellu-
lar role, periostin has broader functions relevant 
to asthma and airway disease. It is a chemotactic 
factor and provides the appropriate matrix sub-
strate for recruitment of blood eosinophils into 
the airways.12 Similarly, periostin is a chemotac-
tic factor for monocyte recruitment from periph-
eral blood into the tissue environment of tumors 
via αVβ3 integrin signaling, where they differen-
tiate into M2-type immunosuppressive macro-
phages.14 The significance of these macrophages is 
that they are proremodeling by providing TGF-β, 
which is a chemotactic and activating factor for 
fibroblasts, and divert arginine metabolism to 
hydroxyproline production, which supports col-
lagen synthesis. Periostin binding to αVβ3 inte-
grins can activate Akt/PKB signaling to increase 
cell survival and can activate nuclear factor κB 
signaling, which is essential for many immune 
cell functions, particularly dendritic cells (DCs). 
Experimental allergic airway inflammation using 
house dust mite allergen was reduced in a postn-/- 
mouse model and this was partly rescued by pas-
sive transfer of wild-type postn-sufficient DCs,10 
suggesting that periostin may have an immuno-
regulatory function by providing a matricellular 
platform for lymphocyte interactions.
The literature above typically supports a strong 
association between periostin and airway disease; 
yet there is an emerging literature that periostin 
might have a protective role in asthma. Postn-/- 
mice sensitized with Aspergillus fumigatus anti-
gen had increased serum IgE, airway responsive-
ness, inflammation, and remodeling compared 
with wild-type mice.15 The authors suggest that 
periostin may form a negative-feedback loop reg-
ulating allergen-induced responses by augment-
ing TGF-β-induced T-regulatory cell differenti-
ation. Thus the suggestion that periostin itself 
could be a potential therapeutic in the treatment 
of atopic disease should be a caution to its use as 
a therapeutic target as discussed in the final para-
graph. In this context of the uncertainty of the 
role of periostin in airway disease, there is added 
value in the depth of the study of Górska et al.6 
They unexpectedly found that there was no cor-
relation between airway tissue periostin expres-
sion levels and protein concentrations, and this 
potentially anomalous observation might be in-
formative of a more dynamic role for periostin 
that has hitherto been unrecognized. It is pos-
sible that periostin has a variety of roles oper-
ating during different phases of disease, for ex-
ample, tethering DCs for initial allergen sensi-
tization, then recruiting eosinophils as disease 
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expression than did cell origin18; therefore, tar-
geting matricellular proteins may hold promise 
for treating the pathogenic remodeling in asth-
ma and COPD. The excess extracellular activity of 
periostin in the lung may be mitigated by an in-
tervention administered during the remodeling 
phase of disease. This could be administered by 
inhalation to avoid affecting its normal function 
in other tissues. Possible interventions could in-
clude humanized periostin-neutralizing antibody, 
equivalent to OC-20 monoclonal antibodies, rep-
licating postn-/- mice that have reduced pathogen-
ic remodeling in experimental asthma.10 Other 
therapeutics could include the vitamin D analog 
22-oxacalcitriol, which might be effective by inhi-
bition of Th2 cytokine- and TGFβ-induced POSTN 
expression or aptamers that bind to periostin and 
antagonize its interaction with integrins and in-
hibit adhesion and migration.19
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